BCR-JAK2 Fusion Protein Expression
1 clinical trials · Condition
◉ Watch BCR-JAK2 Fusion Protein Expression
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434) | William Shomali | 2019-11-15 |
Track BCR-JAK2 Fusion Protein Expression automatically
Every clearance here is in the API, with alerts when new ones post.